ABSTRACT
Objective To explore the expression of human sodium coupled neutral amino acid transporter 1 (SNAT1) in human glioma tissues and its relationship with clinical pathological parameters and prognosis. Methods Immu?nohistochemical and western blotting were used to detect SNAT1 expression in glioma tissue and tumor peripheral tissue from 89 cases of glioma patients including 55 cases of low grade gliomas (WHO I-II), and 34 cases of high grade gliomas (WHO grade III-IV).χ2 test and was used to analyze the relationship between expression and clinical pathological param?eters of SNAT1. Kaplan-Meier method was used to analyze the effect of different expression of SNAT1 on the prognosis of patients and to establish the Cox regression model. Results The expression of SNAT1 was significantly higher in gliomas than in tumor peripheral tissue (t=-9.803, P=0.001). The expression of SNAT1 was significantly higher in high pathologi?cal grade tissues than in low grade of glioma tissues (t=-6.682, P=0.003). SNAT1 expression was associated with tumor di?ameter and pathological grade (χ2=4.963, 8.527, P<0.05);Cox regression model showed that the tumor pathological grade and different SNAT1 protein expression were independent risk factors for the prognosis of patients with glioma. Conclu?sions The expression of SNAT1 protein is closely associated with the pathological grade of gliomas and the prognosis of the patients, which may be a new target to judge the biological characteristics and to evaluate the prognosis of gliomas.